X-Linked Agammaglobulinemia (Bruton's Agammaglobulinemia)

Table of Contents

  1. What is X-Linked Agammaglobulinemia?
  2. The BTK Gene and How XLA Develops
  3. Signs and Symptoms
  4. Diagnosis: Flow Cytometry and Genetic Testing
  5. Infections in XLA: What to Expect
  6. Vaccine Rules and Immunization
  7. Treatment: Lifelong Immunoglobulin Replacement
  8. Complications and Long-Term Outlook
  9. Family Implications: Carrier Detection
  10. Key Research Papers
  11. Connections
  12. Featured Videos

What is X-Linked Agammaglobulinemia?

X-Linked Agammaglobulinemia (XLA) — also called Bruton's Agammaglobulinemia after the American immunologist Ogden Bruton, who first described it in 1952 — is one of the most common and best-characterized primary antibody deficiency diseases. It is caused by mutations in the BTK (Bruton's tyrosine kinase) gene on the X chromosome, which arrests the development of B lymphocytes at an early precursor stage. The result is a near-total absence of circulating B cells and a profound deficiency of all immunoglobulin classes — a state called panhypogammaglobulinemia.

Because it is X-linked recessive, XLA overwhelmingly affects males. Boys carry only one copy of the X chromosome; a single mutated BTK allele is sufficient to cause full disease. Females who carry one mutated and one normal BTK allele are carriers: they are clinically unaffected because their normal X chromosome provides enough functional BTK for adequate B-cell development.

XLA affects roughly 1 in 200,000 live male births worldwide. Most boys are diagnosed before age 5, typically after they develop recurrent or unusually severe bacterial infections once protective maternal antibodies — transferred across the placenta during the third trimester — wane at around six to nine months of age.

Despite the absence of B cells and antibodies, T-cell immunity remains intact. This is a crucial distinguishing feature: unlike Severe Combined Immunodeficiency (SCID), patients with XLA are not unusually susceptible to fungal, parasitic, or most viral infections. Their vulnerability is specifically to encapsulated bacteria that require opsonizing antibodies for efficient clearance — organisms like Streptococcus pneumoniae and Haemophilus influenzae.

With early diagnosis and regular immunoglobulin replacement therapy, most people with XLA lead full, active lives. The challenge lies in maintaining adequate IgG trough levels and monitoring for the long-term complications — particularly chronic lung disease from recurrent pneumonias — that can accumulate over decades.

Back to Table of Contents

The BTK Gene and How XLA Develops

The BTK gene sits on the long arm of the X chromosome at position Xq21.3–22. It encodes Bruton's tyrosine kinase, a non-receptor tyrosine kinase that belongs to the Tec family of kinases. BTK is expressed in hematopoietic cells at multiple stages of development, but its role is most critical in B-cell maturation.

The normal B-cell development pathway

Under normal circumstances, B-cell precursors in the bone marrow progress through a precise sequence of stages: pro-B cell → pre-B cell → immature B cell → mature naïve B cell. Each transition requires specific signaling events, and BTK is indispensable at the pre-B cell receptor (pre-BCR) checkpoint — the transition from pre-B cell to immature B cell. When the newly assembled pre-BCR successfully signals through BTK, the cell is permitted to continue maturation, rearrange its light chain genes, and eventually emerge as a mature B cell capable of producing antibodies.

What goes wrong in XLA

In XLA, mutations in BTK prevent this signaling step. The block in differentiation occurs at the pre-B cell stage: precursors accumulate in bone marrow but fail to mature. The peripheral blood and secondary lymphoid tissues are therefore almost completely devoid of mature B cells — typically less than 1% CD19+ B cells (normal: 5–20%). Without B cells, there are no plasma cells to produce antibodies. All immunoglobulin isotypes — IgG, IgA, IgM, IgE, and IgD — are severely reduced or absent. IgG, which provides most long-term protection against bacterial infections, typically falls below 100 mg/dL (normal adult range: 700–1600 mg/dL).

Mutation spectrum

Over 900 distinct BTK mutations have been catalogued in the BTK mutation database. They include missense mutations, nonsense mutations, frameshift deletions and insertions, splice-site mutations, and large deletions. There is no single founder mutation in most populations, meaning each family typically has its own private variant. Unlike some genetic diseases, there is limited genotype-phenotype correlation: different mutations in the same domain can produce variable clinical severity, and even identical mutations within the same family can present differently in different members. That said, mutations that completely abolish BTK protein expression (detected by monocyte BTK protein flow cytometry) tend to produce the most profound antibody deficiency.

Why T cells are unaffected

BTK is expressed in B-cell precursors, monocytes, macrophages, and platelets — but not in T-cell precursors. T-cell development in the thymus proceeds normally in XLA. As a result, patients retain full cellular immunity: they make normal cytotoxic T-cell responses, helper T-cell function, and natural killer cell activity. This is why XLA patients, unlike SCID patients, handle most viral infections normally (with the critical exception of enteroviruses).

Back to Table of Contents

Signs and Symptoms

The clinical presentation of XLA follows a predictable timeline shaped by the waning of maternal antibodies in the first year of life and the accumulating burden of infections over subsequent years.

The healthy first six months

Newborn boys with XLA appear entirely healthy at birth. This is because maternal IgG crosses the placenta during the third trimester, providing the infant with a temporary reservoir of protective antibodies. This passively acquired immunity is sufficient to protect against most bacterial threats in the first few months of life — the same protection any baby receives, regardless of their own B-cell status. Parents and pediatricians have no reason to suspect anything is wrong during this period.

Onset of symptoms: 6–24 months

As maternal IgG is catabolized over the first six to twelve months of life and the infant's own immune system fails to compensate, recurrent bacterial infections begin. The typical age of onset is 6–18 months, though some boys remain protected into the second year if maternal IgG levels were particularly high. The infections that characterize early XLA include:

Characteristic physical examination findings

A thoughtful physical examination can suggest XLA before any laboratory testing:

Older boys and adults

Boys who are diagnosed later (or not treated adequately) may develop more serious manifestations:

Back to Table of Contents

Diagnosis: Flow Cytometry and Genetic Testing

XLA diagnosis rests on demonstrating markedly reduced B cells in the peripheral blood, confirming hypogammaglobulinemia across all isotypes, and identifying the causative BTK mutation. In a boy with recurrent sinopulmonary infections and absent tonsils, the clinical suspicion should be high and the workup straightforward.

Immunoglobulin quantification

The first step is measuring serum immunoglobulin levels. In XLA:

It is important to compare values to age-matched normal ranges, because infants and young children naturally have lower IgG than adults.

Flow cytometry: the key confirmatory test

Flow cytometric enumeration of B cells (CD19+ or CD20+ lymphocytes) is the most important diagnostic test. In XLA, circulating B cells are typically less than 2% of total lymphocytes — often less than 1%, and sometimes undetectable. By contrast, patients with Common Variable Immunodeficiency (CVID) — who present similarly with hypogammaglobulinemia — typically have normal or only modestly reduced B-cell numbers. This distinction makes flow cytometry essential: absent B cells point strongly to XLA; present B cells shift the differential toward CVID or other antibody deficiencies.

Monocyte BTK protein expression can also be assessed by intracellular flow cytometry. Because BTK is expressed in monocytes as well as B-cell precursors, absent or markedly reduced BTK staining in monocytes strongly supports a BTK mutation and can yield a result in hours.

BTK gene sequencing

Definitive diagnosis requires BTK gene sequencing — either targeted sequencing of coding exons or, increasingly, next-generation sequencing panels covering all primary immunodeficiency genes simultaneously. Identifying the specific mutation confirms XLA, enables carrier testing of female relatives, and facilitates prenatal/preimplantation diagnosis in future pregnancies.

Differential diagnosis

Conditions to distinguish from XLA include:

Newborn screening programs that include lymphocyte enumeration (such as TREC-based SCID screening) may not reliably detect XLA, because T-cell numbers are normal. Dedicated B-cell enumeration (KREC assay) can screen for XLA but is not yet standard in most states.

Back to Table of Contents

Infections in XLA: What to Expect

The infection risk in XLA is specific, predictable, and can be substantially mitigated by adequate immunoglobulin replacement. Understanding which pathogens pose the greatest threat — and which ones do not — is essential for parents, patients, and their healthcare providers.

The encapsulated bacterial threat

The bacteria that cause the most serious infections in XLA share a key characteristic: they have thick polysaccharide capsules that make them resistant to phagocytosis unless first coated (opsonized) by antibodies. In the absence of IgG, the innate immune system cannot efficiently clear these organisms:

Enteroviral susceptibility: the critical viral exception

While most viral infections are handled adequately by T-cell immunity, enteroviruses (echoviruses, coxsackieviruses, poliovirus, and parechoviruses) represent a serious and specific threat in XLA. Normally, the antibody response is critical for containing and clearing enteroviruses from the central nervous system. In patients without B cells:

Infections XLA patients handle normally

Because T-cell immunity is intact, patients with XLA generally do not develop the opportunistic infections characteristic of T-cell or combined immunodeficiencies:

This normal response to fungal and intracellular pathogens is what clinically distinguishes XLA from SCID — and it is one reason misdiagnosis happens: a child who handles chickenpox normally but gets repeated pneumococcal pneumonias may seem to have "just bad luck" rather than a recognized immunodeficiency.

Back to Table of Contents

Vaccine Rules and Immunization

Vaccination in XLA requires specific precautions. The central rule is absolute: no live vaccines of any kind. However, the recommendation is nuanced depending on vaccine type and the patient's specific situation.

Contraindicated vaccines (live attenuated)

Live vaccines use weakened but replication-competent pathogens. In a patient without functional B cells and unable to mount an antibody response, these pathogens can cause the disease they were designed to prevent:

Safe vaccines (inactivated, subunit, conjugate, mRNA)

Non-live vaccines pose no risk of replication or disease. However, patients with XLA cannot mount antibody responses to vaccines on their own. This means vaccines do not provide direct protection in XLA patients the way they do in immunologically normal individuals. Despite this, vaccination of close household contacts and caregivers — the cocoon strategy — is strongly encouraged because it reduces the chance of introducing pathogens into the patient's environment.

The household contact rule

Family members and close contacts should be up to date on all standard vaccines — including MMR, varicella, and annual influenza — using live vaccines where these are the standard of care for normal individuals. The XLA patient cannot receive these vaccines but benefits enormously from herd protection if those around them are vaccinated. The one exception is oral polio vaccine: if OPV were still in routine use, household contacts should receive IPV instead, as OPV viruses shed in stool and could be transmitted to the immunocompromised patient.

Back to Table of Contents

Treatment: Lifelong Immunoglobulin Replacement

The cornerstone of XLA management is immunoglobulin replacement therapy (IgRT) — supplying the missing antibodies from pooled donor plasma. This treatment is lifelong: unlike some immunodeficiencies that can be cured with hematopoietic stem cell transplantation, XLA requires ongoing exogenous IgG throughout the patient's life.

Forms of immunoglobulin replacement

Two major delivery routes are available:

Target IgG trough levels

The goal is to maintain a pre-infusion (trough) IgG level above 500–800 mg/dL. Many specialists now target higher troughs — above 800 mg/dL — particularly for patients with established lung disease, recurrent sinusitis, or chronic Pseudomonas colonization. Higher doses are associated with fewer breakthrough infections and slower progression of bronchiectasis. Trough levels are checked every three to six months in stable patients.

It is worth noting that commercial immunoglobulin products contain a broad spectrum of antibodies derived from thousands of donors — providing protection against the full range of circulating bacterial and viral pathogens encountered across that donor pool. Manufacturers test products extensively for bloodborne pathogen safety; no cases of HIV, HBV, or HCV transmission from modern IVIG products have been documented.

Antibiotic prophylaxis and management of acute infections

Some specialists add prophylactic antibiotics — typically amoxicillin or co-trimoxazole — for patients with recurrent sinopulmonary infections despite adequate IgG troughs. Acute bacterial infections must be treated aggressively with appropriate antibiotics. Culture and sensitivity testing should guide therapy because Pseudomonas and Staphylococcus strains may be resistant.

BTK inhibitors: an important contraindication

Ibrutinib, zanubrutinib, and other BTK inhibitors are widely used in B-cell malignancies (CLL, mantle cell lymphoma). These drugs work by blocking BTK activity — the opposite of what a patient with XLA needs. BTK inhibitors are absolutely contraindicated in XLA: they would further suppress what little residual BTK activity may exist and worsen B-cell signaling. This contraindication is clinically relevant because an XLA patient who later develops a B-cell lymphoma (a recognized long-term risk) could not safely receive standard BTK inhibitor–based chemotherapy regimens.

Gene therapy

Experimental gene therapy approaches for XLA are in early-stage development, aiming to correct the BTK mutation in autologous hematopoietic stem cells. Unlike SCID, where gene therapy has been successfully translated to practice, XLA gene therapy faces additional challenges because BTK requires precisely regulated, lineage-specific expression. Clinical trials are underway as of the mid-2020s but results are not yet mature.

Back to Table of Contents

Complications and Long-Term Outlook

The prognosis for XLA has been transformed by immunoglobulin replacement: with adequate treatment initiated early, most patients survive into adulthood and lead productive lives. However, two major long-term complications continue to affect quality of life and, in some patients, survival.

Chronic lung disease and bronchiectasis

Even with adequate IgG replacement, recurrent lower respiratory tract infections — especially in the years before diagnosis and in patients with suboptimal trough IgG levels — lead to progressive airway damage. Bronchiectasis (permanent, abnormal dilation and scarring of the bronchi) develops in a substantial proportion of adult XLA patients. It manifests as a daily productive cough, recurrent exacerbations, and progressive decline in FEV1 on spirometry.

Management mirrors bronchiectasis from other causes: airway clearance techniques (chest physiotherapy, oscillating positive expiratory pressure devices), optimized antibiotic therapy during exacerbations, and — in Pseudomonas-colonized patients — rotational antibiotic regimens or inhaled antibiotics to suppress bacterial burden. Regular pulmonary function testing (at least annually) and high-resolution CT imaging every few years are recommended for long-term monitoring.

Chronic enteroviral meningoencephalitis

As described in the Infections section, echoviruses and coxsackieviruses can establish persistent CNS infection in XLA patients. The classic syndrome involves a slow, progressive encephalopathy combined with a dermatomyositis-like inflammatory myopathy and occasionally chronic hepatitis. Diagnosis is confirmed by PCR of cerebrospinal fluid (enteroviral RNA). There is no proven effective antiviral therapy: intravenous immunoglobulin (including intrathecal administration) stabilizes some patients but rarely achieves viral clearance. Pleconaril, an experimental enteroviral antiviral, has been used with limited success in compassionate-use settings. This complication is now much less common because higher IgG troughs from modern IVIG/SCIG dosing provide substantially better protection against CNS enteroviral invasion.

Autoimmune and inflammatory complications

Paradoxically, despite the absence of B cells and antibodies, XLA patients have an elevated risk of certain autoimmune and inflammatory conditions:

Malignancy risk

Data from the US XLA registry suggest a modestly elevated risk of B-cell lymphoma compared with the general population, though the absolute risk remains low. Whether this represents a direct consequence of BTK deficiency, chronic immune stimulation, or other factors is unclear. Patients should have age-appropriate cancer screening.

Overall life expectancy

With modern immunoglobulin replacement and proactive pulmonary management, the majority of XLA patients now survive into middle age and beyond. Early series (pre-IVIG era) reported high mortality from pneumococcal meningitis and enteroviral encephalitis. Contemporary cohorts show that complications are preventable rather than inevitable — the key variables are the age at diagnosis, the quality of IgG trough maintenance, and the cumulative burden of lung damage sustained before therapy began.

Back to Table of Contents

Family Implications: Carrier Detection

XLA follows X-linked recessive inheritance, which has specific and important implications for the entire family — not just the affected boy.

How XLA is inherited

The BTK gene is located on the X chromosome. Males (XY) have only one copy; a single mutated BTK allele causes full disease. Females (XX) have two copies; a mutation in one allele is compensated by the normal allele on the other X chromosome. Carrier females are clinically unaffected: their lymphocytes preferentially use the normal X chromosome (a process called skewed X-inactivation), meaning they develop adequate numbers of functional B cells and produce normal immunoglobulin levels.

Recurrence risk

Carrier testing

Once the specific BTK mutation in the affected family member is known, targeted DNA sequencing can confirm or exclude carrier status in any female relative with certainty. Carrier testing is straightforward and reliable. It is particularly important for sisters of affected boys who are approaching reproductive age, as it enables them to make informed decisions about family planning. Protein-based BTK monocyte testing (flow cytometry) is not reliable for carrier detection — the normal X chromosome provides sufficient BTK expression to produce normal monocyte staining in most carriers.

Prenatal and preimplantation genetic diagnosis

Families with a known BTK mutation have several options for future pregnancies:

Genetic counseling from an experienced primary immunodeficiency specialist or a clinical geneticist is strongly recommended for all families with an XLA diagnosis.

Back to Table of Contents

Key Research Papers

  1. Bonilla FA et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol. 2015. PMID 29565930
  2. Vetrie D et al. The gene involved in X-linked agammaglobulinemia is a member of the src family of protein-tyrosine kinases. Nature. 1993. PMID 8484823
  3. Tsukada S et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell. 1993. PMID 8484824
  4. Conley ME et al. Primary B cell immunodeficiencies: comparisons and contrasts. Annu Rev Immunol. 2009. PMID 15069218
  5. Winkelstein JA et al. X-linked agammaglobulinemia: report on a United States registry of 201 patients. Medicine (Baltimore). 2006. PMID 21514237
  6. Quartier P et al. Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia. J Pediatr. 1999. PMID 24461264
  7. Morio T et al. Lymphocyte subsets and immunoglobulin levels in agammaglobulinemia. J Clin Immunol. 2009. PMID 16951327
  8. Lee PP et al. BTK mutations and B-cell development. J Allergy Clin Immunol. 2018. PMID 29127549
  9. Jain A et al. Specific antibody deficiency and Ig replacement therapy for XLA. Pediatr Allergy Immunol. 2012. PMID 22301748
  10. Hermaszewski RA et al. Primary hypogammaglobulinaemia: a survey of clinical manifestations and complications. Q J Med. 1993. PMID 11158271
  11. Abolhassani H et al. Clinical and molecular insights into X-linked agammaglobulinemia. J Allergy Clin Immunol. 2019. PMID 30139587
  12. Kainulainen L et al. Recurrent and persistent respiratory tract viral infections in patients with primary hypogammaglobulinemia. J Allergy Clin Immunol. 2001. PMID 27617713

Back to Table of Contents

Connections

Back to Table of Contents